# Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

> **NCT04016779** · PHASE3 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 374 (actual)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** Placebo
- **DRUG:** SPN-812

## Key facts

- **NCT ID:** NCT04016779
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-20
- **Primary completion:** 2020-10-10
- **Final completion:** 2020-10-10
- **Target enrollment:** 374 (ACTUAL)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04016779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04016779, "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04016779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*